| ![Dia 2](/legacy/block/afbeeldingen/Dia-2-3-3-2011_19-36-41-220x165px.png) | Dia 2 |
|
![Mortality in hospital and at 6 months in low, intermediate and high risk categories in registry populations according to the GRACE Risk score http://www.outcomes.org/grace](/legacy/block/afbeeldingen/Mortality-in-hospital-and-at-6-months-in-low-intermediate-an-220x165px.png) | Mortality in hospital and at 6 months in low, intermediate and high risk categories in registry populations according to the GRACE Risk score http://www.outcomes.org/grace |
| ![Question: Strategy ?](/legacy/block/afbeeldingen/Question-Strategy-3-3-2011_19-36-43-220x165px.png) | Question: Strategy ? |
|
![Relative risk of all cause of mortality](/legacy/block/afbeeldingen/Relative-risk-of-all-cause-of-mortality-220x165px.png) | Relative risk of all cause of mortality |
| ![Management Strategy](/legacy/block/afbeeldingen/Management-Strategy-220x165px.png) | Management Strategy |
|
![Time to catheterization (hrs)](/legacy/block/afbeeldingen/Time-to-catheterization-hrs-3-3-2011_19-36-45-220x165px.png) | Time to catheterization (hrs) |
| ![Dia 8](/legacy/block/afbeeldingen/Dia-8-3-3-2011_19-36-46-220x165px.png) | Dia 8 |
|
![A.S.A.P < 24 h vs delayed > 36h
- ACS met 2/3 > 60 y, pos marker (76%), ischemic ECG (80%) and revasc possible](/legacy/block/afbeeldingen/A-S-A-P-24-h-vs-delayed-36h-ACS-met-2-3-60-y-pos-marker-76-i-220x165px.png) | A.S.A.P < 24 h vs delayed > 36h- ACS met 2/3 > 60 y, pos marker (76%), ischemic ECG (80%) and revasc possible |
| ![No early hazard!](/legacy/block/afbeeldingen/No-early-hazard-220x165px.png) | No early hazard! |
|
![GRACE > 141 14% 21% p=0.009
Major bleeds 3.1 3.5% p=0.53](/legacy/block/afbeeldingen/GRACE-141-14-21-p-0-009-Major-bleeds-3-1-3-5-p-0-53-220x165px.png) | GRACE > 141 14% 21% p=0.009 Major bleeds 3.1 3.5% p=0.53 |
| ![Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h)
N=3000](/legacy/block/afbeeldingen/Early-%e2%89%a424-h-median-14h-or-delayed-intervention-%e2%89%a536-h-median--3-3-2011_19-36-50-220x165px.png) | Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h) N=3000 |
|
![Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h)](/legacy/block/afbeeldingen/Early-%e2%89%a424-h-median-14h-or-delayed-intervention-%e2%89%a536-h-median--3-3-2011_19-36-51-220x165px.png) | Early (≤24 h, median=14h) or delayed intervention ( ≥36 h, median=50h) |
| ![Why not immediately
“STEMI-like”?](/legacy/block/afbeeldingen/Why-not-immediately-%e2%80%9cSTEMI-like%e2%80%9d-220x165px.png) | Why not immediately “STEMI-like”? |
|
![ABOARD study design](/legacy/block/afbeeldingen/ABOARD-study-design-220x165px.png) | ABOARD study design |
| ![Index ACS event](/legacy/block/afbeeldingen/Index-ACS-event-220x165px.png) | Index ACS event |
|
![In-hospital medications](/legacy/block/afbeeldingen/In-hospital-medications-220x165px.png) | In-hospital medications |
| ![Time to catheterization (hrs)](/legacy/block/afbeeldingen/Time-to-catheterization-hrs-3-3-2011_19-36-55-220x165px.png) | Time to catheterization (hrs) |
|
![Primary EP (peak of troponin I)](/legacy/block/afbeeldingen/Primary-EP-peak-of-troponin-I-220x165px.png) | Primary EP (peak of troponin I) |
| ![Composite Ischemic Endpoints at 1 month](/legacy/block/afbeeldingen/Composite-Ischemic-Endpoints-at-1-month-220x165px.png) | Composite Ischemic Endpoints at 1 month |
|
![Safety outcomes at 1 month](/legacy/block/afbeeldingen/Safety-outcomes-at-1-month-220x165px.png) | Safety outcomes at 1 month |
| ![Hospital stay](/legacy/block/afbeeldingen/Hospital-stay-220x165px.png) | Hospital stay |
|
![Summary: TIMACS and ABOARD](/legacy/block/afbeeldingen/Summary-TIMACS-and-ABOARD-220x165px.png) | Summary: TIMACS and ABOARD |
| ![Question: Strategy ?](/legacy/block/afbeeldingen/Question-Strategy-3-3-2011_19-36-59-220x165px.png) | Question: Strategy ? |
|
![Q: GPIIbIIIa inhibitors ? When ?](/legacy/block/afbeeldingen/Q-GPIIbIIIa-inhibitors-When-3-3-2011_19-37-00-220x165px.png) | Q: GPIIbIIIa inhibitors ? When ? |
| ![GPIIbIIIa Inhibitors](/legacy/block/afbeeldingen/GPIIbIIIa-Inhibitors-220x165px.png) | GPIIbIIIa Inhibitors |
|
![Efficacity GPIIBIIIA in NSTE ACS only if PCI !!!](/legacy/block/afbeeldingen/Efficacity-GPIIBIIIA-in-NSTE-ACS-only-if-PCI-220x165px.png) | Efficacity GPIIBIIIA in NSTE ACS only if PCI !!! |
| ![N=2022](/legacy/block/afbeeldingen/N-2022-220x165px.png) | N=2022 |
|
![If GPIIbIIIa:
- Upstream for all high risk NSTE ACS ?
- or selectively downstream if PCI ?](/legacy/block/afbeeldingen/If-GPIIbIIIa-Upstream-for-all-high-risk-NSTE-ACS-or-selectiv-220x165px.png) | If GPIIbIIIa: - Upstream for all high risk NSTE ACS ? - or selectively downstream if PCI ? |
| ![N=9492](/legacy/block/afbeeldingen/N-9492-220x165px.png) | N=9492 |
|
![Delayed Provisional GPIIbIIIa:
Same Ischemic benefit
Lower bleeding risk](/legacy/block/afbeeldingen/Delayed-Provisional-GPIIbIIIa-Same-Ischemic-benefit-Lower-bl-220x165px.png) | Delayed Provisional GPIIbIIIa: Same Ischemic benefit Lower bleeding risk |
| ![30-day Death or MI
Prespecified Subgroups](/legacy/block/afbeeldingen/30-day-Death-or-MI-Prespecified-Subgroups-220x165px.png) | 30-day Death or MI Prespecified Subgroups |
|
![Summary for GPIIbIIIa](/legacy/block/afbeeldingen/Summary-for-GPIIbIIIa-220x165px.png) | Summary for GPIIbIIIa |
| ![Q: GPIIbIIIa inhibitors ? When ?](/legacy/block/afbeeldingen/Q-GPIIbIIIa-inhibitors-When-3-3-2011_19-37-06-220x165px.png) | Q: GPIIbIIIa inhibitors ? When ? |
|
![Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?](/legacy/block/afbeeldingen/Q-Antiplatelet-Therapy-P2Y12-inhibitors-in-CCU-3-3-2011_19-37-07-220x165px.png) | Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ? |
| ![Alternatives Molecules](/legacy/block/afbeeldingen/Alternatives-Molecules-220x165px.png) | Alternatives Molecules |
|
![Montalescot et al. JACC 2006](/legacy/block/afbeeldingen/Montalescot-et-al-JACC-2006-220x165px.png) | Montalescot et al. JACC 2006 |
| ![Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?](/legacy/block/afbeeldingen/Q-Antiplatelet-Therapy-P2Y12-inhibitors-in-CCU-3-3-2011_19-37-09-220x165px.png) | Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ? |
|
![Antiplatelet Drugs](/legacy/block/afbeeldingen/Antiplatelet-Drugs-220x165px.png) | Antiplatelet Drugs |
| ![Study Design, Flow and Compliance](/legacy/block/afbeeldingen/Study-Design-Flow-and-Compliance-220x165px.png) | Study Design, Flow and Compliance |
|
![Clopidogrel: Double vs Standard Dose
Primary Outcome and Components](/legacy/block/afbeeldingen/Clopidogrel-Double-vs-Standard-Dose-Primary-Outcome-and-Comp-220x165px.png) | Clopidogrel: Double vs Standard DosePrimary Outcome and Components |
| ![Clopidogrel: Double vs Standard Dose
Primary Outcome: PCI Patients](/legacy/block/afbeeldingen/Clopidogrel-Double-vs-Standard-Dose-Primary-Outcome-PCI-Pati-220x165px.png) | Clopidogrel: Double vs Standard Dose Primary Outcome: PCI Patients |
|
![Clopidogrel Double vs Standard Dose
Bleeding PCI Population at 30 days](/legacy/block/afbeeldingen/Clopidogrel-Double-vs-Standard-Dose-Bleeding-PCI-Population--220x165px.png) | Clopidogrel Double vs Standard DoseBleeding PCI Population at 30 days |
| ![Conclusions
Clopidogrel Dose Comparison](/legacy/block/afbeeldingen/Conclusions-Clopidogrel-Dose-Comparison-220x165px.png) | ConclusionsClopidogrel Dose Comparison |
|
![ACS (STEMI or UA/NSTEMI) & Planned PCI](/legacy/block/afbeeldingen/ACS-STEMI-or-UA-NSTEMI-Planned-PCI-220x165px.png) | ACS (STEMI or UA/NSTEMI) & Planned PCI |
| ![Primary Endpoint: CV Death,MI,Stroke](/legacy/block/afbeeldingen/Primary-Endpoint-CV-Death-MI-Stroke-220x165px.png) | Primary Endpoint: CV Death,MI,Stroke |
|
![Balance of Efficacy and Safety](/legacy/block/afbeeldingen/Balance-of-Efficacy-and-Safety-3-3-2011_19-38-15-220x165px.png) | Balance of Efficacy and Safety |
| ![ISCHEMIC BENEFIT: subgroups](/legacy/block/afbeeldingen/ISCHEMIC-BENEFIT-subgroups-220x165px.png) | ISCHEMIC BENEFIT: subgroups |
|
![Diabetic Subgroup](/legacy/block/afbeeldingen/Diabetic-Subgroup-220x165px.png) | Diabetic Subgroup |
| ![Ischemic Risk](/legacy/block/afbeeldingen/Ischemic-Risk-220x165px.png) | Ischemic Risk |
|
![BLEEDING RISK: subgroups](/legacy/block/afbeeldingen/BLEEDING-RISK-subgroups-220x165px.png) | BLEEDING RISK: subgroups |
| ![Tailored for Bleeding Risk ?](/legacy/block/afbeeldingen/Tailored-for-Bleeding-Risk-220x165px.png) | Tailored for Bleeding Risk ? |
|
![P2Y12 inhibitors for PCI/ACS in 2011](/legacy/block/afbeeldingen/P2Y12-inhibitors-for-PCI-ACS-in-2011-220x165px.png) | P2Y12 inhibitors for PCI/ACS in 2011 |
| ![Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ?](/legacy/block/afbeeldingen/Q-Antiplatelet-Therapy-P2Y12-inhibitors-in-CCU-3-3-2011_19-38-19-220x165px.png) | Q: Antiplatelet Therapy: P2Y12 inhibitors in CCU ? |
|
![Platelet Function Tests](/legacy/block/afbeeldingen/Platelet-Function-Tests-220x165px.png) | Platelet Function Tests |
| ![Composite of death, non-fatal myocardial infarction, definite stent thrombosis and stroke
POPular study JAMA 2010](/legacy/block/afbeeldingen/Composite-of-death-non-fatal-myocardial-infarction-definite--220x165px.png) | Composite of death, non-fatal myocardial infarction, definite stent thrombosis and stroke POPular study JAMA 2010 |
|
![Cut-Off values Based on Clinical Endpoints
in Prospective Studies](/legacy/block/afbeeldingen/Cut-Off-values-Based-on-Clinical-Endpoints-in-Prospective-St-220x165px.png) | Cut-Off values Based on Clinical Endpoints in Prospective Studies |
| ![Risk for recurrent events concentrated in patients with highest on-treatment reactivity](/legacy/block/afbeeldingen/Risk-for-recurrent-events-concentrated-in-patients-with-high-220x165px.png) | Risk for recurrent events concentrated in patients with highest on-treatment reactivity |
|
![POPular Risc Score](/legacy/block/afbeeldingen/POPular-Risc-Score-220x165px.png) | POPular Risc Score |
| ![Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial](/legacy/block/afbeeldingen/Ticagrelor-compared-with-clopidogrel-in-patients-with-acute--220x165px.png) | Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial |
|
![Ticagrelor (AZD 6140):
an oral reversible P2Y12 antagonist](/legacy/block/afbeeldingen/Ticagrelor-AZD-6140-an-oral-reversible-P2Y12-antagonist-3-3-2011_19-38-25-220x165px.png) | Ticagrelor (AZD 6140): an oral reversible P2Y12 antagonist |
| ![PLATO study design](/legacy/block/afbeeldingen/PLATO-study-design-220x165px.png) | PLATO study design |
|
![K-M estimate of time to first primary efficacy
event (composite of CV death, MI or stroke)](/legacy/block/afbeeldingen/K-M-estimate-of-time-to-first-primary-efficacy-event-composi-220x165px.png) | K-M estimate of time to first primary efficacy event (composite of CV death, MI or stroke) |
| ![Time to major bleeding – primary safety event](/legacy/block/afbeeldingen/Time-to-major-bleeding-%e2%80%93-primary-safety-event-220x165px.png) | Time to major bleeding – primary safety event |
|
![Non-CABG and CABG-related major bleeding](/legacy/block/afbeeldingen/Non-CABG-and-CABG-related-major-bleeding-220x165px.png) | Non-CABG and CABG-related major bleeding |
| ![Safety = TIMI Major Non-CABG Bleeds (12-15 months)](/legacy/block/afbeeldingen/Safety-TIMI-Major-Non-CABG-Bleeds-12-15-months-3-3-2011_19-38-29-220x165px.png) | Safety = TIMI Major Non-CABG Bleeds (12-15 months) |
|
![Conclusions](/legacy/block/afbeeldingen/Conclusions-3-3-2011_19-38-30-220x165px.png) | Conclusions |
| ![2011
CURRENT vs PLATO vs TRITON](/legacy/block/afbeeldingen/2011-CURRENT-vs-PLATO-vs-TRITON-220x165px.png) | 2011 CURRENT vs PLATO vs TRITON |
|
![Platelet Aggregation at 4 hours](/legacy/block/afbeeldingen/Platelet-Aggregation-at-4-hours-220x165px.png) | Platelet Aggregation at 4 hours |
| ![TRITON and PLATO](/legacy/block/afbeeldingen/TRITON-and-PLATO-220x165px.png) | TRITON and PLATO |
|
![Safety = TIMI Major Non-CABG Bleeds (12-15 months)](/legacy/block/afbeeldingen/Safety-TIMI-Major-Non-CABG-Bleeds-12-15-months-3-3-2011_19-38-33-220x165px.png) | Safety = TIMI Major Non-CABG Bleeds (12-15 months) |
| ![Tailor-made medicine?](/legacy/block/afbeeldingen/Tailor-made-medicine-220x165px.png) | Tailor-made medicine? |
|
![Marked interindividual response to antiplatelet drugs](/legacy/block/afbeeldingen/Marked-interindividual-response-to-antiplatelet-drugs-220x165px.png) | Marked interindividual response to antiplatelet drugs |
| ![Residual or On-Treatment Platelet Reactivity](/legacy/block/afbeeldingen/Residual-or-On-Treatment-Platelet-Reactivity-220x165px.png) | Residual or On-Treatment Platelet Reactivity |
|
![Do Platelet Function Assays Predict Clinical Outcomes in clopidogrel pretreated patients undergoing elective PCI
The POPular-study. JAMA 2010;303:754-62](/legacy/block/afbeeldingen/Do-Platelet-Function-Assays-Predict-Clinical-Outcomes-in-clo-220x165px.png) | Do Platelet Function Assays Predict Clinical Outcomes in clopidogrel pretreated patients undergoing elective PCI The POPular-study. JAMA 2010;303:754-62 |
| ![Tests more physiological shear-dependent](/legacy/block/afbeeldingen/Tests-more-physiological-shear-dependent-220x165px.png) | Tests more physiological shear-dependent |
|
![POPular Risk Score](/legacy/block/afbeeldingen/POPular-Risk-Score-220x165px.png) | POPular Risk Score |
| ![Rate of CABG patients and TIMI Major Bleeds](/legacy/block/afbeeldingen/Rate-of-CABG-patients-and-TIMI-Major-Bleeds-220x165px.png) | Rate of CABG patients and TIMI Major Bleeds |
|
![Summmary: P2Y12 inhibition for tomorrow](/legacy/block/afbeeldingen/Summmary-P2Y12-inhibition-for-tomorrow-220x165px.png) | Summmary: P2Y12 inhibition for tomorrow |
| ![Compliance and ST](/legacy/block/afbeeldingen/Compliance-and-ST-220x165px.png) | Compliance and ST |
|
![With more potent P2Y12 inhibitors:
How to reduce Bleeding Risk in ACS ?](/legacy/block/afbeeldingen/With-more-potent-P2Y12-inhibitors-How-to-reduce-Bleeding-Ris-220x165px.png) | With more potent P2Y12 inhibitors:How to reduce Bleeding Risk in ACS ? |
| ![Low Dose of Aspirin](/legacy/block/afbeeldingen/Low-Dose-of-Aspirin-220x165px.png) | Low Dose of Aspirin |
|
![ASA Dose Comparison
Primary Outcome and Bleeding](/legacy/block/afbeeldingen/ASA-Dose-Comparison-Primary-Outcome-and-Bleeding-220x165px.png) | ASA Dose ComparisonPrimary Outcome and Bleeding |
| ![Use of PPI](/legacy/block/afbeeldingen/Use-of-PPI-220x165px.png) | Use of PPI |
|
![Radial Access](/legacy/block/afbeeldingen/Radial-Access-220x165px.png) | Radial Access |
| ![Case](/legacy/block/afbeeldingen/Case-220x165px.png) | Case |
|
![3/3/2011](/legacy/block/afbeeldingen/3-3-2011-3-3-2011_19-38-45-220x165px.png) | 3/3/2011 |
| ![3/3/2011](/legacy/block/afbeeldingen/3-3-2011-3-3-2011_19-38-46-220x165px.png) | 3/3/2011 |
|
![Similar for DES](/legacy/block/afbeeldingen/Similar-for-DES-220x165px.png) | Similar for DES |
| ![MACC with BMS and non-cardiac surgery N=899](/legacy/block/afbeeldingen/MACC-with-BMS-and-non-cardiac-surgery-N-899-220x165px.png) | MACC with BMS and non-cardiac surgery N=899 |
|
![Bleeds with DES and Non-cardiac Surgery](/legacy/block/afbeeldingen/Bleeds-with-DES-and-Non-cardiac-Surgery-220x165px.png) | Bleeds with DES and Non-cardiac Surgery |
| ![Bridging?](/legacy/block/afbeeldingen/Bridging-220x165px.png) | Bridging? |
|
![Summary for ACS: 2011](/legacy/block/afbeeldingen/Summary-for-ACS-2011-220x165px.png) | Summary for ACS: 2011 |
| ![Discharge therapy](/legacy/block/afbeeldingen/Discharge-therapy-220x165px.png) | Discharge therapy |
|
![Tailored Therapy PCI in ACS ?](/legacy/block/afbeeldingen/Tailored-Therapy-PCI-in-ACS-220x165px.png) | Tailored Therapy PCI in ACS ? |
| ![Discontinue antithrombotica](/legacy/block/afbeeldingen/Discontinue-antithrombotica-220x165px.png) | Discontinue antithrombotica |
|
Deel deze pagina met collega's en vrienden: